Ruxolitinib Efficacy and Safety in Pediatric AD

Panelists discuss how newer studies exploring JAK-targeting creams for children with mild to moderate atopic dermatitis (AD) demonstrate encouraging efficacy and sustained response. Many patients experience visible improvement and reduced itch within weeks, with benefits maintained over time.

Panelists also highlight favorable safety profiles, noting that adverse effects are generally mild and limited to the treatment area. These outcomes support expanding nonsteroidal options for children, reducing reliance on corticosteroids for long-term control.

Caregiver feedback reinforces the value of well-tolerated, easy-to-apply therapies that integrate smoothly into daily life, enhancing consistency and confidence.